A significant difference was found between the HSP70 and S100B measurements of the study and control groups before and after RT (P=0.001 and p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVE This study aimed to evaluate the difference between serum levels of S100B and HSP70 in the non-meta- static, Luminal A breast cancer (BC) patients with the healthy population, and determine the impact of post-operative radiotherapy (RT) on serum markers.
📊
Key Findings & Data:METHODS 21 BC patients who underwent chest wall/breast±axillary RT after adjuvant chemotherapy and twenty- one healthy individuals were included in the study group.
💡
Conclusion & Impact:A significant difference was found between the HSP70 and S100B measurements of the study and control groups before and after RT (P=0.001 and p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
OBJECTIVE This study aimed to evaluate the difference between serum levels of S100B and HSP70 in the non-meta- static, Luminal A breast cancer (BC) patients with the healthy population, and determine the impact of post-operative radiotherapy (RT) on serum markers. METHODS 21 BC patients who underwent chest wall/breast±axillary RT after adjuvant chemotherapy and twenty- one healthy individuals were included in the study group. The changes in serum HSP70 and S100B levels were observed in the study and control groups. RESULTS A total of 42 participants were included. A significant difference was found between the HSP70 and S100B measurements of the study and control groups before and after RT (P=0.001 and p
🔖
Cite This Article
ÖZER, E. E., IŞIKSAÇAN, N., SOYDEMİR, G. P., ERDAL, G. Ş., GEDİKBAŞI, A., BÖLÜKBAŞ, M. K. (2022). Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. Türk Onkoloji Dergisi, Cilt: 37 - Sayı: 2, 115–121. https://ajindex.com/articles/639057
Ahmad A. Breast Cancer Statistics: Recent Trends. Adv Exp Med Biol 2019;1152:1–7
Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team work- ing on breast cancer survival: retrospective, compar- ative, interventional cohort study of 13 722 women. BMJ 2012;344:e2718
Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fi- etkau R, et al. Current controversies in RT for breast cancer. Radiat Oncol 2017;12:25
Jagsi R. Progress and controversies: radiation ther- apy for invasive breast cancer. CA Cancer J Clin 2014;64(2):135–52
Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al; American Society of Clin- ical Oncology. Breast cancer follow-up and manage- ment after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(7):961–5
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 2016;34(9):927
Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008;100(16):1179
Soysal SD, Tzankov A, Muenst SE. Role of the Tumor Microenvironment in Breast Cancer. Pathobiology 2015;82(3–4):142–52
Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. Breast 2013;22(suppl 2):50–6
Harpio R, Einarsson R. S100 proteins as can- cer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004;37(7):512–8
Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tu- morigenesis. Trends Biochem Sci 2006;31(3):164–72
Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, et al. Suppression of heat shock pro- tein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A 2012;109(22):8699– 704
Yun CW, Kim HJ, Lim JH, Lee SH. heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells 2019;9(1):60
Bentzen SM, Parliament M, Deasy JO, Dicker A, Cur- ran WJ, Williams JP, et al. Biomarkers and surrogate endpoints for normal-tissue effects of radiation ther- apy: the importance of dose-volume effects. Int J Ra- diat Oncol B